36234-66-9

Basic information

• Product Name: 2-aMino-6,7-dihydro-5H-benzothiazol-4-one
• Synonyms: 2-aMino-6,7-dihydro-5H-benzothiazol-4-one;2-amino-6,7-dihydrobenzo[d]thiazol-4(5H)-one;2-amino-6,7-dihydro-4(5H)-Benzothiazolone
• CAS NO: 36234-66-9
• Molecular Formula: C7H8N2OS
• Molecular Weight: 168.21622
• Mol File: 36234-66-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 376.0±11.0 °C(Predicted)
• Appearance: /
• Density: 1.428±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.70±0.20(Predicted)
• CAS DataBase Reference: 2-aMino-6,7-dihydro-5H-benzothiazol-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-6,7-dihydro-5H-benzothiazol-4-one(36234-66-9)
• EPA Substance Registry System: 2-aMino-6,7-dihydro-5H-benzothiazol-4-one(36234-66-9)

Safety Data

• Hazardous Substances Data: 36234-66-9(Hazardous Substances Data)

Usage

Chemical compound

2-Amino-6,7-dihydro-5H-benzothiazol-4-one

Derivative

Benzothiazole derivative

Use

Intermediate in the synthesis of pharmaceutical drugs

Applications

Organic synthesis, medicinal chemistry

Biological activity

Exhibits biological activity

Antitumor properties

Derivatives studied for antitumor properties

Antibacterial properties

Derivatives studied for antibacterial properties

Neuroprotective effects

Potential neuroprotective effects

Role in neurodegenerative diseases

Investigated for possible role in treatment of neurodegenerative diseases

Upstream product

• 36234-65-8 (E)-3-amino-2-thiocyanatocyclohex-2-enone 
• 5220-49-5 3-amino-cyclohex-2-enone 
• 24829-91-2 3-bromocyclohexane-1,2-dione 
• 17356-08-0 thiourea 
• 765-87-7 cyclohexane-1,2-dione 

Downstream Products

• 70590-48-6 6,7-dihydrobenzo[d]thiazol-4(5H)-one 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted hydrazone compounds, methods of making such compounds and metal complexes thereof, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds and metal complexes to treat, prevent or ameliorate cancer are provided.

Azole derivatives as histamine H3 receptor antagonists, Part I: Thiazol-2-yl ethers

Most human histamine H3 receptor (hH3R) antagonists follow a general structural blueprint, containing a basic moiety linked by a spacer to a substituted core element. In this investigation the acceptance of thiazol-2-yl ether moieties in the core region is proved with some ether derivatives showing hH3R binding affinities in the nanomolar concentration range. A diversity of structural motifs is used as substituents to enhance the in vitro hH3R binding affinity.